FAST NEWS: Wuxi Bio’s Subsidiary Removed from U.S. ‘Unverified’ List
The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Monday its WuXi Biologics Co. Ltd. subsidiary has been removed from the “unverified” list maintained by the U.S. Commerce Department, following…
RELATED ARTICLES
-
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG -
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK
-
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
-
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK 603259.SHG
-
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK 603259.SHG
-
FAST NEWS: WuXi Biologics boosts new projects target
2269.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
